FDA clears Sensei’s IND to start Phase I/II therapy trial of SNS-101

The US Food and Drug Administration (FDA) has granted clearance for Sensei Biotherapeutics’ investigational new drug (IND) application for SNS-101 enabling the initiation of a Phase I/II clinical trial to treat solid tumours.